Lesson plan

Evenamide

Evenamide ( ; developmental codes NW-3509 and NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Na v 1.3, Na v 1.7, and Na v 1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy. Enigma TRS -1 and -2 Phase 3 trials were announced in late 2025.

Back to article

Article summary

Evenamide ( ; developmental codes NW-3509 and NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Na v 1.3, Na v 1.7, and Na v 1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy. Enigma TRS -1 and -2 Phase 3 trials were announced in late 2025.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.